Ali H; Chander C; Torbenson E; Hsia B; Silberstein PT · 2026 · Anticancer research
Paper
BACKGROUND/AIM: Leiomyosarcoma is a rare and aggressive malignant smooth muscle tumor with limited treatment options and poor outcomes. Large-scale molecular characterization is needed to better understand tumor biology and support precision oncology, as prior studies have been limited by small cohort sizes, single-institution data, and restricted gene panels. This study aimed to characterize clinicogenomic features of leiomyosarcoma using the AACR Project GENIE 19.0 public dataset. PATIENTS AND METHODS: We analyzed 1,017 tumor samples from 957 patients, evaluating demographic patterns, somatic mutation frequencies, copy number alterations, and genomic co-occurrence and exclusivity across primary and metastatic disease sites. RESULTS: Females comprised 65.7% of cases and White patients 61.4%. The most frequently altered genes were TP53 (50.3%), RB1 (17.9%), and ATRX (15.9%), followed by KMT2D, MED12, NOTCH1, ATM, PTEN, ROS1, FAT1, BRCA2, and NOTCH3. Recurrent copy number alterations included RB1 homozygous deletion (24.4%), MAP2K4 amplification (18.4%), and TP53 homozygous deletion (15.5%). Significant co-occurrence was observed among TP53, RB1, ATRX, and PTEN alterations (q<0.05). Most genomic alterations were driven by primary tumors, whereas metastatic samples showed enrichment of IGF2 and AXIN1 alterations. CONCLUSION: These findings highlight recurrent alterations in TP53, RB1, and ATRX and suggest potential roles for IGF2 and AXIN1 in leiomyosrcoma metastatic disease that warrant further investigation.
Analysis
This study characterizes the clinicogenomic features of leiomyosarcoma using a large public dataset to identify recurrent genomic alterations and potential drivers of metastatic disease.
Source record